G01N 2333/4703
Regulators
Official title: Regulators; Modulating activity
G01N2333/4703 (Regulators) appears on 765 US grants and 1,554 published applications in this corpus.
Search patents in G01N- Granted patents
- 765
- Published applications
- 1,554
- Assignees
- 853
- Inventors
- 3,255
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 4 | 0 |
| 1998 | 3 | 0 |
| 1999 | 4 | 0 |
| 2000 | 2 | 0 |
| 2001 | 6 | 2 |
| 2002 | 8 | 8 |
| 2003 | 4 | 29 |
| 2004 | 6 | 19 |
| 2005 | 4 | 29 |
| 2006 | 13 | 32 |
| 2007 | 8 | 32 |
| 2008 | 11 | 36 |
| 2009 | 14 | 53 |
| 2010 | 20 | 51 |
| 2011 | 28 | 63 |
| 2012 | 26 | 63 |
| 2013 | 18 | 57 |
| 2014 | 29 | 51 |
| 2015 | 52 | 168 |
| 2016 | 48 | 173 |
| 2017 | 71 | 96 |
| 2018 | 67 | 113 |
| 2019 | 66 | 68 |
| 2020 | 61 | 55 |
| 2021 | 52 | 76 |
| 2022 | 37 | 52 |
| 2023 | 21 | 44 |
| 2024 | 32 | 58 |
| 2025 | 27 | 70 |
| 2026 | 21 | 56 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Tau-binding antibodies29 Sep 2026US 12,747,288 B2Ucb Biopharma Srl
- RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition15 Sep 2026US 12,735,707 B2Massachusetts Eye and Ear Infirmary
- Compositions and methods for monitoring, diagnosis, detection and treatment of cancer8 Sep 2026US 12,728,115 B2GLAX Health LLC
- Diagnostic and drug screening for molecular signatures of early onset sporadic parkinson's disease18 Aug 2026US 12,708,611 B2Cedars-Sinai Medical Center
- Methods for identification, assessment, prevention, and treatment of metabolic disorders using SLIT211 Aug 2026US 12,702,694 B2Dana-Farber Cancer Institute, Inc.
- Compositions and methods for detection of aberrant cdk5 expression8 Oct 2026US 2026/0309712 A1Arizona Board of Regents on Behalf of the University of Arizona
- Quantitative immunoassay for the detection of autoantibodies to nephrin1 Oct 2026US 2026/0298924 A1EUROIMMUN Medizinische Labordiagnostika AG
- Anti-human homeobox protein nkx-2.1 antibodies for use in immunohistochemistry (ihc) protocols and for diagnosing cancer24 Sep 2026US 2026/0285955 A1Agilent Technologies, Inc.
- Inhibitors of ets2-activating molecules for the treatment of inflammatory diseases17 Sep 2026US 2026/0273081 A1The Francis Crick Institute Limited
- Method and kit for the diagnosis of oral carcinoma17 Sep 2026US 2026/0276642 A1
Most cited
By later US patents
- Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors127US 7,078,180 B2The Children’s Hospital of Philadelphia · 2006
- Methods for determining isolated p27 protein levels and uses thereof115US 6,316,208 B1Fred Hutchinson Cancer Research Center · 2001
- Marker associated with non-alcoholic steatohepatitis95US 9,060,981 B2Mochida Pharmaceutical Co., Ltd. · 2015
- Use of AIM3 acting as a tumor suppressor88US 7,902,165 B2Seoul National University Industry Foundation · 2011
- Methods for treating an inflammatory disease of the bowel84US 7,998,474 B2Rowett Research Institute · 2011